Home » Pfizer to Acquire CovX to Bolster Biologics Pipeline
Pfizer to Acquire CovX to Bolster Biologics Pipeline
Pfizer reports that it has agreed to buy CovX to enhance its biotherapeutics portfolio. The acquisition gives Pfizer three new early-stage compounds and a technology platform.
Genetic Engineering & biotechnology News
Genetic Engineering & biotechnology News
Upcoming Events
-
07May
-
14May
-
30May